<?xml version="1.0" encoding="UTF-8"?>
<p>We conducted in‚Äêclinic visits on day 2 and at weeks 1, 6, 12, 26, and 52. We assessed safety by evaluating the incidence of adverse events, assessing vital signs, physical examinations, radiological evaluations, clinical and immunological laboratory testing and electrocardiography. A telephone call at week 104 was made to inquire about newly developed malignancies.</p>
